Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00096213 · ClinicalTrials.gov registry record · Phase 2

S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone

A Phase 2 study of Sarcoma, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
20
Study locations

NCT00096213 is a Phase 2 study of Sarcoma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 60 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00096213, a Phase 2 study of Sarcoma, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.

Conditions Studied

Sarcoma

Interventions

  • PROCEDURE conventional surgery

Study Locations (20)

Washington

  • St. Joseph Cancer Center - Bellingham
  • Olympic Hematology and Oncology - Bremerton
  • Skagit Valley Hospital Cancer Care Center - Mount Vernon
  • Fred Hutchinson Cancer Research Center - Seattle
  • Harborview Medical Center - Seattle
  • Minor and James Medical, PLLC - Seattle
  • Group Health Central Hospital - Seattle
  • Swedish Cancer Institute at Swedish Medical Center - First Hill Campus - Seattle
  • Polyclinic First Hill - Seattle
  • University Cancer Center at University of Washington Medical Center - Seattle

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor
  • William Beaumont Hospital - Royal Oak Campus - Royal Oak

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora

Florida

  • University of Florida Shands Cancer Center - Gainesville

New Mexico

  • University of New Mexico Cancer Research and Treatment Center - Albuquerque

Ohio

  • Akron City Hospital - Akron

Oregon

  • Oregon Health & Science University Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2004-12
Est. Completion 2009-08
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00096213

The ClinicalTrials.gov registry entry for NCT00096213 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which conventional surgery is the first listed.

NCT00096213 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Washington, Michigan, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00096213 about?

NCT00096213 is a clinical study titled "S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone". RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.

What is the current status of trial NCT00096213?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-12. Estimated completion is 2009-08.

What conditions does trial NCT00096213 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00096213?

The interventions under investigation include: conventional surgery (PROCEDURE).

Who is sponsoring clinical trial NCT00096213?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00096213 being conducted?

This trial has 20 study locations across Arkansas, Colorado, Florida, Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.